Balancing Comfort and Success: Post-retrieval Ketorolac in Fresh Embryo Transfers

What this Trial Is About

Researchers are evaluating the use of ketorolac, a medication often used for pain relief after surgery, in patients undergoing in vitro fertilization (IVF) who plan to have a fresh embryo transfer five days after egg retrieval. The study aims to determine if giving ketorolac intravenously after egg retrieval affects important IVF outcomes such as implantation and live birth rates. This is a double-blind randomized controlled trial addressing concerns about ketorolac's effects on bleeding and embryo implantation. Participants will be randomly assigned to receive either 30 mg of ketorolac through an IV immediately after egg retrieval while still under sedation or no ketorolac at all, with all other IVF care remaining the same. The embryo transfer will occur on day five post-retrieval as planned. The trial uses a 1:1 randomization method and includes patients undergoing standard ovarian stimulation protocols. During the study, researchers will collect extensive medical and reproductive history as well as treatment details from medical records for up to 45 weeks. They will monitor pain levels, narcotic use, time to discharge, need for additional evaluations for pain or bleeding, and IVF outcomes including implantation, clinical pregnancy, miscarriage, and live birth rates. The primary outcome is the implantation rate confirmed by ultrasound about six weeks after egg retrieval.

Ketorolac Use and Fresh Embryo Transfer Outcomes